It has been a new dawn in bespoke medical therapies for thyroid eye disease since the FDA approval of Teprotumumab in the USA.
BOPSS have assembled a panel of TED Trial Investigators and other experts who can share their experiences and perspectives, to encourage wider UK participation and increase patient access to these exciting new therapies in the blossoming trial landscape.
Thank you to our hosts Jonathan Norris, Tristan McMullan and Manoj Parulekar for organising a marvellous meeting in Oxford....
Read MoreWe are saddened to hear of the recent death of Rick Anderson, a true pioneer in the field of...
Read MoreThe next Honorary Secretary and Honorary Treasurer of BOPPS will be Katya Tambe (Nottingham) and Austin McCormick (Aintree) respectively....
Read MoreAs the returning officer for the recent Presidential Elections it gives me great pleasure to announce that the next...
Read MoreThe new RCOphth ‘Inspire’ online learning platform is launching soon, and will provide education on all aspects of ophthalmology...
Read MoreBOPSS is proud to provide partnership support to the first on-line International Symposium on Wartime Ophthalmic Trauma, organised by ASOPRS....
Read MoreSave the date. BOPSS face to face in Manchester: 15th -17th June 2022 BOPSS is looking forward to its first...
Read MoreBOPSS would like to recognise that our trainees have had very little chance to present to a national audience...
Read MoreThis symposium is a joint-venture between the Royal College of Ophthalmologists and BOPPS. We hope to showcase updates in...
Read MoreIn view of government advice and lockdown into late Spring 2021, the Executive has made a decision to postpone...
Read More
